Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 361Lung Neoplasms 195Breast Neoplasms 163Ovarian Neoplasms 129Triple Negative Breast Neoplasms 79Squamous Cell Carcinoma of Head and Neck 73Small Cell Lung Carcinoma 67Fallopian Tube Neoplasms 56Head and Neck Neoplasms 46Carcinoma, Ovarian Epithelial 44Neoplasms 40Neoplasm Metastasis 39Esophageal Neoplasms 36Adenocarcinoma of Lung 36Esophageal Squamous Cell Carcinoma 29Prostatic Neoplasms 27Endometrial Neoplasms 27Uterine Cervical Neoplasms 23Brain Neoplasms 23Central Nervous System Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Squamous Cell 21Recurrence 20Neuroblastoma 20Lymphoma, Large B-Cell, Diffuse 20Melanoma 19Lymphoma 19Carcinoma 19Adenocarcinoma, Bronchiolo-Alveolar 18Testicular Neoplasms 15

Interventions

pemigatinib 5Rogaratinib 2pembrolizumab 1lenvatinib 1infigratinib 1erdafitinib 1brivanib 1Rabeprazole 1Irinotecan 1INCB 54828-101 1Gemcitabine 1E-3810 1Drug Combinations 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Acrocephalosyndactylia × Carboplatin × Clear all
NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Incyte Corporation

Phase 2 Terminated
7 enrolled 10 charts
Genitourinary

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡